These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17040191)

  • 1. Complementary new approaches enable repositioning of failed drug candidates.
    Tartaglia LA
    Expert Opin Investig Drugs; 2006 Nov; 15(11):1295-8. PubMed ID: 17040191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
    Cockburn IM; Henderson RM
    J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 4. New estimates of drug development costs.
    Frank RG
    J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
    [No Abstract]   [Full Text] [Related]  

  • 5. [Development of new drugs is too expensive].
    Andreasen J
    Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic possibilities of interference RNA.
    López Tricas JM
    Farm Hosp; 2012; 36(3):115-7. PubMed ID: 22137610
    [No Abstract]   [Full Text] [Related]  

  • 7. The pharmaceutical industry and research in 2002 and beyond.
    Dutta AS; Garner A
    Drug News Perspect; 2003 Dec; 16(10):637-48. PubMed ID: 14747843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in risks associated with new drug development: success rates for investigational drugs.
    DiMasi JA; Feldman L; Seckler A; Wilson A
    Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notable deals in the pharmaceutical industry in the fourth quarter of 2016.
    D'Souza P
    Drugs Today (Barc); 2017 Jan; 53(1):75-82. PubMed ID: 28387386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can complexity be commercialized?
    Mack GS
    Nat Biotechnol; 2004 Oct; 22(10):1223-9. PubMed ID: 15470456
    [No Abstract]   [Full Text] [Related]  

  • 13. The decline in new drug development.
    Rumore MM
    Am Pharm; 1992 Apr; NS32(4):73-8. PubMed ID: 1566739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fewer new drugs from the pharmaceutical industry.
    Taylor D
    BMJ; 2003 Feb; 326(7386):408-9. PubMed ID: 12595352
    [No Abstract]   [Full Text] [Related]  

  • 15. Fee structure for investigational drug studies.
    Anandan JV; Isopi MJ; Warren AJ
    Am J Hosp Pharm; 1993 Nov; 50(11):2339-43. PubMed ID: 8266958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative antibacterial drugs: nothing ventured, nothing gained.
    Stein J
    Expert Opin Investig Drugs; 2005 Feb; 14(2):107-9. PubMed ID: 15757389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HGS drug flop latest genomics setback.
    Reid B
    Nat Biotechnol; 2002 Jun; 20(6):533. PubMed ID: 12042841
    [No Abstract]   [Full Text] [Related]  

  • 19. Challenges and opportunities of drug repositioning.
    Novac N
    Trends Pharmacol Sci; 2013 May; 34(5):267-72. PubMed ID: 23582281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies.
    Schwarz SW; Oyama R
    J Nucl Med; 2015 Apr; 56(4):497-500. PubMed ID: 25766895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.